Recruiting
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
NCT06321081
- Conditions
- Colonic Diseases, Colorectal Neoplasms, Digestive System Diseases, +11 more
- Locations
-
- Beijing Hospital Beijing, Beijing Municipality, China